Floatz logo

Acalabrutinib

Follicular Lymphoma

Patrick C. Johnson, MDSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

196 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Vincristine Sulfate
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

Acalabrutinib is also rated in:

B-cell chronic lymphocytic leukemiaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →